Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and efficacy of Smoflipid compared to standard of care lipid emulsion
Intralipid 20% administered via a central vein in pediatric patients 3 months to 16 years of
age who require parenteral nutrition for at least 90 days and up to 1 year.